Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. DFTX
7. GOOGL
8. MU
9. IBM
10. HOOD

Go back to Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease
(NASDAQ: VRDN) Delayed: 17.63 +1.00 (6.01%)
Previous Close $16.63    52 Week High $ 
Open $16.93    52 Week Low $ 
Day High $18.18    P/E N/A 
Day Low $16.93    EPS $ 
Volume 2,549,627